Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

The first step is to label sample cells with fluorescent dye ... a quick and accurate way to count CD4 + and CD8 + T cells in HIV-infected patients. Until recently flow cytometers and the ...

Then there’s lenacapavir, a shot that protects people from HIV. Named “breakthrough of ... including immune blood cells, and are critical for treating blood disease. BEACON is open-label and ...

Intense global research is now exploring the clinical potential of CAR T-cell therapies beyond blood cancers, with therapies in development targeting solid tumours, autoimmune diseases, and infectious ...

The blood center’s product testing lab verified the blood type and ensured it contained no viruses, such as HIV or West Nile.

Human immunodeficiency virus type 1 (HIV-1) targets important cells of our immune system, making infected individuals more ...

HIV has become a more manageable condition in recent years, but a full cure remains elusive. Now, scientists have found ...

A map of deadly infectious diseases known to attack the central nervous system (CNS) of people who are already suffering with ...

Stanford researchers highlight the potential of EBC-46, a compound derived from Australia’s blushwood tree, in eradicating HIV. Acting as a potent latency-reversing agent, EBC-46 activates dormant ...

Scientists have unveiled insights into how HIV-1, the virus responsible for AIDS, skillfully hijacks cellular machinery for its own survival. By dissecting the molecular interplay between the virus ...

Flushing HIV out into the open For the new study, the researchers set out to examine EBC-46's value as a "latency reversing agent." These agents kickstart certain pathways in latent cells infected ...